-
NMPA Approves Sinocelltech’s Finotonlimab for Head and Neck Cancer
•
The National Medical Products Administration (NMPA) of China has approved Sinocelltech Group Ltd’s (SHA: 688520) finotonlimab, a programmed-death 1 (PD-1) monoclonal antibody (mAb), for use in combination with platinum-based chemotherapy as a first-line treatment for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Sunshine Lake Pharma’s Antaitasvir…
-
Sunshine Lake Pharma Files for HKEX IPO, Expanding Global Pharmaceutical Reach
•
China-based Sunshine Lake Pharma Co., Ltd has submitted an initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKEX), with the unit price and other key details yet to be announced. The exclusive sponsor for this IPO is CICC, a leading financial institution. Established Pharmaceutical Company with a…
-
3SBio Inc. Secures Licensing Deal with Sunshine Lake Pharma for Clifutinib Commercialization
•
China-based 3SBio Inc. (HKG: 1530) has announced a licensing deal with fellow Chinese firm Sunshine Lake Pharma Co., Ltd., a member of HEC Group (SHA: 600673), concerning the commercialization of clifutinib in mainland China. Under the terms of the agreement, 3SBio will handle the commercialization efforts for the drug, paying…
-
Sunshine Lake Pharma Inks Licensing Deal with Apollo Therapeutics for APL-18881
•
China-based Sunshine Lake Pharma Co., Ltd., (HKG: 1558) a member of the HEC Group, has entered into a licensing agreement with UK-headquartered Apollo Therapeutics Group Limited for the development of APL-18881 (HEC88473). This strategic deal grants Apollo exclusive rights to develop and commercialize the drug outside of Greater China, while…
-
HEC Pharma Overturns Patent Decision Against Novartis’ Gilenya
•
China-based generics firm HEC Pharma has managed to overturn a previous final decision in a patent dispute with Swiss pharmaceutical giant Novartis AG (NYSE: NVS) over the multiple sclerosis blockbuster drug Gilenya (fingolimod). In January 2022, the US Court of Appeals for the Federal Circuit (CAFC) had dismissed an appeal…
